Kinase Inhibitors of Novel Pyridopyrimidinone Candidates: Synthesis and In Vitro Anticancer Properties

Figure 6

The interaction between compound 6 and EGFR kinase protein (PDB code: 4HJO), presented by MOE 2015: (a, d) 3D compound 6 binding geometry (yellow sticks) in the CDK6 binding site cavity. (b) 2D interaction diagram of compound 6 with the CDK6 binding site cavity. (c) 2D diagrams of compound 6 (green) and erlotinib (red) were overlapping.